Decision to widen access to brentuximab vedotin for systemic anaplastic large cell lymphoma

We have made the decision to widen access to brentuximab vedotin for systemic anaplastic large cell lymphoma from 1 April 2026.  We expect this will improve the lives of around 12-13 people in New Zealand per year.Thank you to all those who provided feedback in response to the consultation, your feedback is appreciated. You can find more information on this decision on the Pharmac website including our responses to key points raised by consultees.

• Decision to widen access to brentuximab vedotin for systemic anaplastic large cell lymphoma

  
  

Ngā mihi

___________________________________________________________________

Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington

P: 0800 660 050 | www.pharmac.govt.nz